WinstonWınston
Siemens Healthineers AG logo

Siemens Healthineers AG

SEMHF
55
Medical - Devices · Healthcare
Price
$46.66
+0.00 (+0.00%)
Market Cap
$52.23B
Exchange
Other OTC
Winston Score
55
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 9, 2026 · filings through Jun 30, 2026

Share count rising — dilution

+1.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.10B (2021) → 1.12B (2025)

Siemens Healthineers makes medical equipment and software used in hospitals and clinics around the world. Its core products include MRI machines, CT scanners, X-ray systems, and laboratory diagnostic tools. The company also provides cancer treatment technology through its Varian division, which it acquired in 2021, making Siemens Healthineers one of the largest medical technology companies in the world.

The company earns money by selling imaging equipment, diagnostic instruments, and related software, as well as through service contracts and consumables that generate recurring revenue. It operates globally, with strong presence in Europe, North America, and Asia, and reported roughly $23 billion in annual revenue in its most recent fiscal year. Its large installed base of equipment creates switching costs, since hospitals tend to stick with familiar systems and service providers. The key growth driver is expanding demand for advanced diagnostics and cancer care, while currency fluctuations and pricing pressure in competitive imaging markets remain ongoing risks.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+1.6% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+20.4% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$2.0B/ year

Flat (+2% vs prior year)

8.4% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

76.1%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$3.3B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Siemens Healthineers AG is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
42.5%
Healthy — 42.5% gross margin
Operating Margin
17.7%
Healthy — 17.7% operating margin
ROCE
3.0%
Weak — 3.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+10.0%
Steady sales growth (+10.0% YoY)
EPS YoY
+2.1%
Flat earnings

Single-digit earnings growth — steady but not exciting.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
137%
Turns 137% of profit into real cash
FCF Margin
8.6%
Modest free cash flow (8.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.76
Moderate — manageable debt (0.76)
Interest Cover
7.56x
Adequate interest coverage (7.6x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
23.7x
Growth-priced — P/E 23.7

P/E above the market average. People are paying up for expected growth.

P/E vs Forward
+8.5
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (23.7 → 15.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
2.71%
Moderate income — 2.71% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth
+22.8%
Dividend growing fast (22.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial